Table 4.
Univariate Analyses of Progression-Free and Overall Survival Among Eligible Patients
| Parameter | Progression-Free Survival |
Overall Survival |
||
|---|---|---|---|---|
| Median (months) | Log-Rank P | Median (months) | Log-Rank P | |
| All eligible patients | 2.9 | — | 5.6 | — |
| Treatment* | ||||
| GEM | 2.6 | .09 | 4.9 | .15 |
| GEM FDR | 3.5 | 6.2 | ||
| GEM + oxaliplatin | 2.7 | 5.7 | ||
| Age, years | ||||
| 55-69 | 2.8 | .65 | 5.6 | .63 |
| 70+ | 3.0 | 5.5 | ||
| Under 55 | 3.3 | 5.7 | ||
| Sex | ||||
| Female | 2.7 | .40 | 5.6 | .40 |
| Male | 3.3 | 5.7 | ||
| Race | ||||
| Hispanic | 2.6 | .69 | 6.0 | .80 |
| Non-Hispanic black | 2.2 | 4.8 | ||
| Non-Hispanic white | 3.2 | 5.7 | ||
| Other | 2.0 | 4.3 | ||
| ECOG performance status | ||||
| 0 | 3.6 | < .01 | 6.8 | < .01 |
| 1 | 2.8 | 5.3 | ||
| 2 | 2.1 | 3.9 | ||
| Disease status | ||||
| Locally advanced | 5.4 | < .01 | 9.2 | < .01 |
| Metastatic | 2.7 | 5.4 | ||
| Previous 6-month weight loss | ||||
| < 5% | 2.4 | .02 | 5.3 | .27 |
| 5-< 10% | 3.4 | 6.1 | ||
| 10-< 20% | 3.4 | 5.5 | ||
| 20% or more | 2.8 | 6.0 | ||
| Prior RT | ||||
| No | 5.5 | 0.52 | 2.9 | .53 |
| Yes | 6.9 | 3.1 | ||
| Prior adjuvant chemotherapy | ||||
| No | 5.5 | .10 | 3.0 | .14 |
| Yes | 7.3 | 2.9 | ||
| Prior surgery | ||||
| No | 5.5 | < .01 | 2.8 | .06 |
| Yes | 7.2 | 3.4 | ||
| History of DVT or prior embolus | ||||
| No | 5.8 | < .01 | 3.1 | .02 |
| Yes | 4.5 | 2.5 | ||
| Disease measurable or not | ||||
| Both | 5.3 | < .01 | 2.7 | .12 |
| Measurable | 6.8 | 3.6 | ||
| Nonmeasurable | 5.4 | 2.8 | ||
Abbreviations: GEM, gemcitabine; GEM FDR, gemcitabine fixed-dose rate; GEMOX, gemcitabine 1,000 mg/m2/100 minutes/day 1 plus oxaliplatin 100 mg/m2/day 2 every 14 days; ECOG, Eastern Cooperative Oncology Group; RT, radiotherapy; DVT, deep vein thrombosis.
*
Stratified by strata at random assignment.